230 related articles for article (PubMed ID: 18468818)
1. Clinical experiences with drospirenone: from reproductive to postmenopausal years.
Pérez-López FR
Maturitas; 2008 Jun; 60(2):78-91. PubMed ID: 18468818
[TBL] [Abstract][Full Text] [Related]
2. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
3. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers WH
Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
Sangthawan M; Taneepanichskul S
Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
6. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
Fruzzetti F; Lazzarini V; Ricci C; Quirici B; Gambacciani M; Paoletti AM; Genazzani AR
Contraception; 2007 Sep; 76(3):190-4. PubMed ID: 17707715
[TBL] [Abstract][Full Text] [Related]
7. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
[TBL] [Abstract][Full Text] [Related]
8. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
Oelkers W
Mol Cell Endocrinol; 2004 Mar; 217(1-2):255-61. PubMed ID: 15134826
[TBL] [Abstract][Full Text] [Related]
9. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V
Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739
[TBL] [Abstract][Full Text] [Related]
10. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
11. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
Foidart JM; Faustmann T
Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
[TBL] [Abstract][Full Text] [Related]
12. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
13. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
Palacios S; Foidart JM; Genazzani AR
Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
[TBL] [Abstract][Full Text] [Related]
14. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
[TBL] [Abstract][Full Text] [Related]
15. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
Rübig A
Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
White WB; Pitt B; Preston RA; Hanes V
Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
19. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
[TBL] [Abstract][Full Text] [Related]
20. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
